These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 22190441)

  • 1. Influence of severity of anemia on clinical findings in infants with sickle cell anemia: analyses from the BABY HUG study.
    Lebensburger JD; Miller ST; Howard TH; Casella JF; Brown RC; Lu M; Iyer RV; Sarnaik S; Rogers ZR; Wang WC;
    Pediatr Blood Cancer; 2012 Oct; 59(4):675-8. PubMed ID: 22190441
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG).
    Wang WC; Ware RE; Miller ST; Iyer RV; Casella JF; Minniti CP; Rana S; Thornburg CD; Rogers ZR; Kalpatthi RV; Barredo JC; Brown RC; Sarnaik SA; Howard TH; Wynn LW; Kutlar A; Armstrong FD; Files BA; Goldsmith JC; Waclawiw MA; Huang X; Thompson BW;
    Lancet; 2011 May; 377(9778):1663-72. PubMed ID: 21571150
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of hydroxyurea treatment on renal function parameters: results from the multi-center placebo-controlled BABY HUG clinical trial for infants with sickle cell anemia.
    Alvarez O; Miller ST; Wang WC; Luo Z; McCarville MB; Schwartz GJ; Thompson B; Howard T; Iyer RV; Rana SR; Rogers ZR; Sarnaik SA; Thornburg CD; Ware RE;
    Pediatr Blood Cancer; 2012 Oct; 59(4):668-74. PubMed ID: 22294512
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive "switching" agent. The Multicenter Study of Hydroxyurea in Sickle Cell Anemia.
    Charache S; Barton FB; Moore RD; Terrin ML; Steinberg MH; Dover GJ; Ballas SK; McMahon RP; Castro O; Orringer EP
    Medicine (Baltimore); 1996 Nov; 75(6):300-26. PubMed ID: 8982148
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of hydroxyurea on clinical events in the BABY HUG trial.
    Thornburg CD; Files BA; Luo Z; Miller ST; Kalpatthi R; Iyer R; Seaman P; Lebensburger J; Alvarez O; Thompson B; Ware RE; Wang WC;
    Blood; 2012 Nov; 120(22):4304-10; quiz 4448. PubMed ID: 22915643
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genotoxicity associated with hydroxyurea exposure in infants with sickle cell anemia: results from the BABY-HUG Phase III Clinical Trial.
    McGann PT; Flanagan JM; Howard TA; Dertinger SD; He J; Kulharya AS; Thompson BW; Ware RE;
    Pediatr Blood Cancer; 2012 Aug; 59(2):254-7. PubMed ID: 22012708
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hydroxyurea and growth in young children with sickle cell disease.
    Rana S; Houston PE; Wang WC; Iyer RV; Goldsmith J; Casella JF; Reed CK; Rogers ZR; Waclawiw MA; Thompson B;
    Pediatrics; 2014 Sep; 134(3):465-72. PubMed ID: 25157002
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The pediatric hydroxyurea phase III clinical trial (BABY HUG): challenges of study design.
    Thompson BW; Miller ST; Rogers ZR; Rees RC; Ware RE; Waclawiw MA; Iyer RV; Casella JF; Luchtman-Jones L; Rana S; Thornburg CD; Kalpatthi RV; Barredo JC; Brown RC; Sarnaik S; Howard TH; Luck L; Wang WC
    Pediatr Blood Cancer; 2010 Feb; 54(2):250-5. PubMed ID: 19731330
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hydroxyurea is associated with lower costs of care of young children with sickle cell anemia.
    Wang WC; Oyeku SO; Luo Z; Boulet SL; Miller ST; Casella JF; Fish B; Thompson BW; Grosse SD;
    Pediatrics; 2013 Oct; 132(4):677-83. PubMed ID: 23999955
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Massive accidental overdose of hydroxyurea in a young child with sickle cell anemia.
    Miller ST; Rey K; He J; Flanagan J; Fish BJ; Rogers ZR; Wang WC; Ware RE;
    Pediatr Blood Cancer; 2012 Jul; 59(1):170-2. PubMed ID: 21744485
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic modifiers of sickle cell anemia in the BABY HUG cohort: influence on laboratory and clinical phenotypes.
    Sheehan VA; Luo Z; Flanagan JM; Howard TA; Thompson BW; Wang WC; Kutlar A; Ware RE;
    Am J Hematol; 2013 Jul; 88(7):571-6. PubMed ID: 23606168
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interventions for preventing silent cerebral infarcts in people with sickle cell disease.
    Estcourt LJ; Kimber C; Hopewell S; Trivella M; Doree C; Abboud MR
    Cochrane Database Syst Rev; 2020 Apr; 4(4):CD012389. PubMed ID: 32250453
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel use Of Hydroxyurea in an African Region with Malaria (NOHARM): a trial for children with sickle cell anemia.
    Opoka RO; Ndugwa CM; Latham TS; Lane A; Hume HA; Kasirye P; Hodges JS; Ware RE; John CC
    Blood; 2017 Dec; 130(24):2585-2593. PubMed ID: 29051184
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hydroxyurea (hydroxycarbamide) for sickle cell disease.
    Nevitt SJ; Jones AP; Howard J
    Cochrane Database Syst Rev; 2017 Apr; 4(4):CD002202. PubMed ID: 28426137
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Abdominal ultrasound with scintigraphic and clinical correlates in infants with sickle cell anemia: baseline data from the BABY HUG trial.
    McCarville MB; Luo Z; Huang X; Rees RC; Rogers ZR; Miller ST; Thompson B; Kalpatthi R; Wang WC;
    AJR Am J Roentgenol; 2011 Jun; 196(6):1399-404. PubMed ID: 21606305
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interventions for preventing silent cerebral infarcts in people with sickle cell disease.
    Estcourt LJ; Fortin PM; Hopewell S; Trivella M; Doree C; Abboud MR
    Cochrane Database Syst Rev; 2017 May; 5(5):CD012389. PubMed ID: 28500860
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interventions for chronic kidney disease in people with sickle cell disease.
    Roy NB; Fortin PM; Bull KR; Doree C; Trivella M; Hopewell S; Estcourt LJ
    Cochrane Database Syst Rev; 2017 Jul; 7(7):CD012380. PubMed ID: 28672087
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment.
    Steinberg MH; Barton F; Castro O; Pegelow CH; Ballas SK; Kutlar A; Orringer E; Bellevue R; Olivieri N; Eckman J; Varma M; Ramirez G; Adler B; Smith W; Carlos T; Ataga K; DeCastro L; Bigelow C; Saunthararajah Y; Telfer M; Vichinsky E; Claster S; Shurin S; Bridges K; Waclawiw M; Bonds D; Terrin M
    JAMA; 2003 Apr; 289(13):1645-51. PubMed ID: 12672732
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Minireview: Prognostic factors and the response to hydroxurea treatment in sickle cell disease.
    Wang WC
    Exp Biol Med (Maywood); 2016 Apr; 241(7):730-6. PubMed ID: 27026724
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictors of fetal hemoglobin response in children with sickle cell anemia receiving hydroxyurea therapy.
    Ware RE; Eggleston B; Redding-Lallinger R; Wang WC; Smith-Whitley K; Daeschner C; Gee B; Styles LA; Helms RW; Kinney TR; Ohene-Frempong K
    Blood; 2002 Jan; 99(1):10-4. PubMed ID: 11756146
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.